The results from the EORTC 10994/BIG 1–00 study of patients with locally advanced breast cancer receiving NAC showed that breast cancer subtypes, including HER2 + with or without trastuzumab and triple-negative, are predictive factors for high LRR after NAC [16]. This evidence concerns the gene ERBB2 and breast cancer.